

## EMCREG-INTERNATIONAL MEMBER DISCLOSURE INFORMATION

### Important Considerations:

A relationship is "**relevant**" if the relationship or interest relates to the topic in terms of any of the following: the same or similar subject matter or topic; the same, similar or competing drug or device, product or service, intellectual property or asset; a drug or device company or its competitor; or has the reasonable potential to result in financial, professional or other personal gain or loss for you, members of your household or employer.

Please classify each relationship as either "**Modest**" or "**Significant**." A relationship is considered to be "**Significant**" if (a) the person receives \$10,000 or more during any 12 month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns \$10,000 or more of the fair market value of the entity. A relationship is considered to be "**Modest**" if it is less than "**Significant**" under the preceding definition.

1. **J. Douglas Kirk, MD**
2. **Date: 8-28-06**
3. **Employment:** UC Davis Medical Center
4. **Research Grants** (includes principal investigator, collaborator or consultant and pending grants as well as grants already received):

Status of Grant	Funding Agency	Title of Grant	Dates	Amount of Grant	PI or Co-Investigator
Complete	Genentech Inc.	National Registry of Myocardial Infarction	1999 - 2003	\$1,000 annually	Principal Investigator
Complete	COR Therapeutics, Inc.	ItrACS Registry – Internet Tracking of Acute Coronary Syndrome	2000– 2003	\$28,000	Co-Principal Investigator
Complete	SCIOS, Inc.	Prospective Randomized Outcomes Study of Acutely Decompensated CHF Treated Initially in Outpatients with Natrecor: The PROACTION TRIAL	2001-2003	\$55,000 projected	Principal Investigator
Complete	COR Therapeutics, Inc.	Integrilin and Tenecteplase in Acute Myocardial Infarction (The Integriti Study)	2001 – 2003	\$48,000	Investigator
Complete	Ischemia Technologies, Inc.	Evaluation of Albumin Cobalt Binding test for use as an aid to the diagnosis of cardiac ischemia	2001 - 2002	\$67,000 projected	Principal Investigator
Complete	COR Therapeutics, Inc.	EARLY Trial – Eptfibatide for Acute Coronary Syndromes: Rapid Administration vs. Late Administration – Therapeutic Yield	2000 – 2001	\$17,000	Principal Investigator
Active	COR Therapeutics, Inc.	CRUSADE Registry – Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcome with Early Implementation of the ACC/AHA Guidelines	2001 – Present	\$10,000 annually	Principal Investigator

Complete	Aventis Pharmaceuticals	A prospective, Open label, Randomized, parallel Group Investigation to Evaluate the Efficiency and Safety of versus unfractionated in Subjects who Present to the Emergency Department with ACS (Rescue-ACS)	2002 - Present	\$30,000	Principal Investigator
Complete	Roche Diagnostics	Rapid PCR-Based Diagnosis of Pathogens in Sepsis	2002-2003	\$250,000	Investigator
Complete	INNERCOOL Therapeutics	ICE-IT Intravascular Cooling Adjunctive to Percutaneous coronary Intervention (ICE-IT)	2003 - Present	\$54,540	Investigator
<b>Status of Grant</b>	<b>Funding Agency</b>	<b>Title of Grant</b>	<b>Dates</b>	<b>Amount of Grant</b>	<b>PI or Co-Investigator</b>
Complete	Inovise Medical	Audiocor gallop detection for ACS	2004-2006	\$10,000	Principal Investigator
Complete	Scios, Inc.	ADHERE Registry	2005-2006	\$7,500 annually	Principal Investigator
Active	Accumetrics, Inc.	Aspirin resistance study	2005-present	\$14,500	Principal Investigator
Active	Inovise Medical	HeARD-IT trial	2005-present	\$20,000	Co-Investigator
Pending	Protein Design Labs	Phase II, Ularitide in Acute Heart Failure	2006	\$35,000	Principal Investigator
Complete	EMF Grant	Nesiritide in Heart Failure	2005-present	\$50,000	Co-Investigator

5. **Other Research Support** (includes receipt of drugs, supplies, equipment or other-in-kind support):

6. **Speakers Bureaus** (includes speakers bureau, symposia, and expert witness):

Biosite  
Schering Inc  
Sanofi-aventis  
PDL Biopharma  
Scios Inc

7. **Ownership Interest** (includes stock, stock options, partnership, membership or other equity position in an entity regardless of form of the entity, or any option or right to acquire such position, and any rights in any patent or other intellectual property):

**None**

8. **Consultant/Advisory Board:**

National Steering Committee – *CRUSADE Registry of Acute Coronary Syndrome Patients*.

Scientific Advisory Board- ADHERE-EM Registry of Heart Failure Patients.

Scientific Advisory Board- Phase II randomized, double blind, placebo-controlled study of ularitide in the treatment of patients with acute decompensated heart failure URGENT Trial).

Industry Consultant to: Biosite, Schering Inc, Sanofi-aventis, PDL Biopharma, Scios Inc, Accumetrics, Inovise Medical

9. **Other:**